Anecova, a Swiss medtech company focusing on the development of innovative Assisted Reproductive Technologies (ART) to enhance fertility, has closed a financing round. The funds were raised by BV Holding, private investors and a fund specialised in Life Sciences. They will facilitate further development of the Anecova’s device, AneVivo.
Following the launch and commercialisation of their AneVivo device on the market, Anecova announced the first success results. In September the startup reported that first babies had already been conceived using AneVivo Natural Fertilisation treatment, since summer this year.
Today the startup has reached yet another milestone. With participation from BV Holding AG, private investors and a fund specialising in Life sciences, Anecova has successfully closed a financing round in which it raised CHF 5 million. As part of a financing round, BV Holding contributed CHF 1.5 million, while other investors contributed CHF 3.5 million. The funding raised through this round will be used by Anecova for market development, further development of the AneVivo procedure and studies on potential benefits of the AneVivo procedure.
Anecova developed the AneVivo Instrument, natural approach to assisted reproductive technology in Collaboration with world-leading scientists and physicians. AneVivo is a porous capsule device allowing bi-directional passage of fluids, nutrients, and other non-cellular components, to enable interaction between the embryos and the maternal environment. It allows fertilisation and very early embryo development directly within the maternal womb.
About Anecova
Anecova is a Swiss medical device company based at the EPFL Innovation Park in Lausanne. Anecova is working with world leading scientists and clinicians in the field of Assisted Reproductive Technology (ART) with the objective of developing more natural approaches to Assisted Reproductive Techniques (ART). The company is ISO certified (9001 and 13485). Its AneVivo device is European Certified (CE MARK) and has also received the approval of several regulators in Europe, including the HFEA in the UK. Anecova has been working in the past years in the development of a device allowing the fertilization and embryo development in the maternal environment instead of in a laboratory. AneVivo, Anecova’s first commercialized device, allows clinics to offer Natural Fertilization treatments to their patients.
(RAN)
Please login or sign up to comment.
Commenting guidelines